EGFR and breast carcinoma: For Factor 12 which is associated with breast cancer (Fig. 2e), the same integrative analysis reveals higher ERBB2 and ESR1 expression (Fig. 2b and Supplementary Fig. 8B) coupled with, amongst other, ERBB/MAPK/mTOR/Notch signaling (Fig. 2f) and shows sensitivity for Afatinib (BIBW2992), which targets ERBB2 (Fig. 2g).